WeightWatchers can still profit off dieters ‘puking their guts out’ after taking Ozempic: analyst
WeightWatchers’ stock has taken a beating with the rise of breakthrough dieting drugs — but the company can still profit from members who are “puking their guts out” after taking medications like Ozempic, according to a Wall Street analyst.
Shares of WW International plunged 25% on Thursday she conceded last year amid widespread speculation about her slimmed-down figure.
While Winfrey’s exit has fueled questions about WeightWatchers’ relevance, weight-loss patients still “need advice on what to do when they over-ate at a restaurant and are now puking their guts out” because of the side effects of drugs like Ozempic or Wegovy, according to DA Davidson analyst Linda Bolton Weiser.
“They need advice on what to do with their flabby excess skin once they have lost 100 pounds,” Bolton Weiser wrote in a Monday research note to clients. “That’s why an investor would buy WeightWatchers instead of Eli Lily or Nordisk.”
Bolton Weiser has a ‘buy’ rating of WeightWatchers and a price target of $12.50.
